EXEL vs PFE
EXEL: Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline of next-generation small molecules and antibody-drug conjugates. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | EXEL | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $54.98 | $24.82 | |
| Market cap as of 2026-07-23 | $14.0B | $142.0B | |
| P/E as of 2026-07-23 | 16.74 | 18.96 | EXEL lower |
| PEG as of 2026-07-23 | 1.09 | -3.38 | PFE lower |
| Net margin as of 2026-07-23 | +35.1% | +11.8% | EXEL higher |
| Gross margin as of 2026-07-23 | +96.4% | +74.8% | EXEL higher |
| Operating margin as of 2026-07-23 | +39.4% | +15.4% | EXEL higher |
| ROE as of 2026-07-23 | +40.2% | +8.4% | EXEL higher |
| ROA as of 2026-07-23 | +30.5% | +3.6% | EXEL higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.72 | EXEL lower |
| Revenue growth (YoY) as of 2026-07-23 | +7.9% | +1.4% | EXEL higher |
| Revenue CAGR (3y) SEC XBRL | +9.5% | -14.8% | EXEL higher |
| Dividend yield as of 2026-07-23 | n/a | +6.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.41 | 0.28 | |
| 1-year return as of 2026-07-22 close | +26.8% | -1.3% | EXEL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.